- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Polyrizon Ltd.: Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform | 303 | GlobeNewswire (Europe) | Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative... ► Artikel lesen | |
| Mo | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | Polyrizon Ltd. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 08.04. | Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements | 1 | GlobeNewswire (USA) | ||
| 08.04. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 07.04. | Polyrizon beschafft 3,5 Mio. US-Dollar über registrierte Direktplatzierung | 2 | Investing.com Deutsch | ||
| 07.04. | Polyrizon sichert sich 3,5 Mio. US-Dollar über Direktplatzierung | 1 | Investing.com Deutsch | ||
| 07.04. | Polyrizon raises $3.5M through registered direct offering | 1 | Investing.com | ||
| 26.03. | Polyrizon reports $17.5M cash position, advances FDA discussions | 1 | Investing.com | ||
| 26.03. | Polyrizon Ltd.: Polyrizon Provides 2025 and Recent Highlights | 189 | GlobeNewswire (Europe) | Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions... ► Artikel lesen | |
| 26.03. | Polyrizon reports FY results: GAAP EPS of $4.90 | 1 | Seeking Alpha | ||
| 25.03. | Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 | 5 | GlobeNewswire (USA) | ||
| 25.03. | Polyrizon Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 24.03. | Polyrizon Signs MOU To Acquire Up To 20% Stake In Colugo; Stock Plunges In Pre-market | - | RTTNews | ||
| 24.03. | Polyrizon signs MOU to acquire 20% stake in drone maker Colugo | 3 | Investing.com | ||
| 24.03. | Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo | 6 | Seeking Alpha | ||
| 24.03. | Polyrizon Ltd.: Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications | 365 | GlobeNewswire (Europe) | The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel... ► Artikel lesen | |
| 17.03. | Polyrizon beauftragt CRO für Biokompatibilitätsstudien seiner Medizintechnik | - | Investing.com Deutsch | ||
| 17.03. | Polyrizon signs CRO agreement for biocompatibility studies | 1 | Investing.com | ||
| 17.03. | Polyrizon Ltd.: Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program | 240 | GlobeNewswire (Europe) | Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions... ► Artikel lesen |
1 2 3 4 5 Weiter >>
88 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,510 | -2,11 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| NOVAVAX | 6,660 | -2,63 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 21,930 | 0,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BIOXXMED | 0,905 | +0,56 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,988 | +2,49 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,390 | 0,00 % | COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on the development of natural... ► Artikel lesen | |
| XOMA ROYALTY | 34,800 | -1,14 % | XFRA X0M1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILXOMA ROYALTY DL... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-K, Annual Report | ||
| PHIO PHARMACEUTICALS | 1,185 | -2,07 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ORAGENICS | - | - | Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal... ► Artikel lesen | |
| VIVUS | - | - | VIVUS B.V.: VIVUS Reinforces QSIVA's Clinical Efficacy and Safety in Obesity Management | - QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 11,400 | -2,56 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer | Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) ("Tenax"... ► Artikel lesen | |
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | Unity Biotechnology, Inc. - 15-12G, Securities registration termination | ||
| SERES THERAPEUTICS | 6,150 | +3,02 % | Seres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Readout of investigator-sponsored SER-155 study in immune checkpoint-related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track... ► Artikel lesen |
POLYRIZON LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 15,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.